Hydrophilic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human blood-brain barrier

References

• Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, Burchard EG, Giacomini KM. (2006). Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 318:521–529.
   PubMed Web of Science ®Google Scholar
• Bergström M, Yates R, Wall A, Kågedal M, Syvänen S, Långström B. (2006). Blood-brain barrier penetration of zolmitriptan–modelling of positron emission tomography data. J Pharmacokinet Pharmacodyn 33:75–91.
   PubMedGoogle Scholar
• Braggio S, Montanari D, Rossi T, Ratti E. (2010). Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates. Expert Opin Drug Discov 5:609–618.
   PubMed Web of Science ®Google Scholar
• Bronger H, König J, Kopplow K, Steiner HH, Ahmadi R, Herold-Mende C, Keppler D, Nies AT. (2005). ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 65:11419–11428.
   PubMed Web of Science ®Google Scholar
• Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866–871.
   PubMed Web of Science ®Google Scholar
• Enokizono J, Kusuhara H, Ose A, Schinkel AH, Sugiyama Y. (2008). Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos 36:995–1002.
   PubMed Web of Science ®Google Scholar
• Evans DC, O’Connor D, Lake BG, Evers R, Allen C, Hargreaves R. (2003). Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos 31:861–869.
   PubMed Web of Science ®Google Scholar
• Franke RM, Scherkenbach LA, Sparreboom A. (2009). Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics 10:339–344.
   PubMed Web of Science ®Google Scholar
• Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. (2000). Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 294:73–79.
   PubMed Web of Science ®Google Scholar
• Gao B, Stieger B, Noé B, Fritschy JM, Meier PJ. (1999). Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47:1255–1264.
   PubMed Web of Science ®Google Scholar
• Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB. (2007). Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 81:362–370.
   PubMed Web of Science ®Google Scholar
• Hassan NJ, Pountney DJ, Ellis C, Mossakowska DE. (2006). BacMam recombinant baculovirus in transporter expression: a study of BCRP and OATP1B1. Protein Expr Purif 47:591–598.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236.
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. (2009). Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693–705.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Triplett BA. (2004). Characterization of GhRac1 GTPase expressed in developing cotton (Gossypium hirsutum L.) fibers. Biochim Biophys Acta 1679:214–221.
   PubMedGoogle Scholar
• Kullak-Ublick GA, Hagenbuch B, Stieger B, Schteingart CD, Hofmann AF, Wolkoff AW, Meier PJ. (1995). Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 109:1274–1282.
   PubMed Web of Science ®Google Scholar
• Kusuhara H, Sugiyama Y. (2005). Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2:73–85.
   PubMedGoogle Scholar
• Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, Leake BF, Kim RB. (2005). Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 280:9610–9617.
   PubMed Web of Science ®Google Scholar
• Mandery K, Bujok K, Schmidt I, Keiser M, Siegmund W, Balk B, König J, Fromm MF, Glaeser H. (2010). Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol 80:1746–1753.
   PubMed Web of Science ®Google Scholar
• Moriyama Y, Hiasa M, Matsumoto T, Omote H. (2008). Multidrug and toxic compound extrusion (MATE)-type proteins as anchor transporters for the excretion of metabolic waste products and xenobiotics. Xenobiotica 38:1107–1118.
   PubMed Web of Science ®Google Scholar
• Ose A, Kusuhara H, Endo C, Tohyama K, Miyajima M, Kitamura S, Sugiyama Y. (2010). Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. Drug Metab Dispos 38:168–176.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2005). The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3–14.
   PubMedGoogle Scholar
• Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW. (2006). In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34:786–792.
   PubMed Web of Science ®Google Scholar
• Sakai Y, Dobson C, Diksic M, Aubé M, Hamel E. (2008). Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis. Neurology 70:431–439.
   PubMed Web of Science ®Google Scholar
• Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, Jeffrey P. (2007). Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322:205–213.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC. (2010). Does sumatriptan cross the blood-brain barrier in animals and man? J Headache Pain 11:5–12.
   PubMed Web of Science ®Google Scholar
• Wang Q, Rager JD, Weinstein K, Kardos PS, Dobson GL, Li J, Hidalgo IJ. (2005). Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm 288:349–359.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wu Z, Li D, Wang D, Wang X, Feng X, Xia M. (2011). Involvement of oxygen-regulated protein 150 in AMP-activated protein kinase-mediated alleviation of lipid-induced endoplasmic reticulum stress. J Biol Chem 286:11119–11131.
   PubMed Web of Science ®Google Scholar
• Zhou L, Schmidt K, Nelson FR, Zelesky V, Troutman MD, Feng B. (2009). The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug Metab Dispos 37:946–955.
   PubMed Web of Science ®Google Scholar